Why Bristol-Myers Squibb Could Break Out This Year

As today’s WSJ reports, there is growing interest in running clinical trials that repurpose drugs that have already won FDA approval for another disease.

Move could open the door to cheaper generic versions of biological drugs.

REMOTE is the first-ever ran­domized clinical trial under an in­vestigational new drug (IND) application in which the study is managed entirely us­ing electronic tools and allows subjects to participate in the clinical trial regardless of their proximity to clinical sites. Pfizer’s pi­lot project uses mobile phone and Web-based technology to collect necessary data for the trial, without clinic visits. The trial was announced last June. And this month  ACT, Editor-in-Chief Lisa Henderson talked t

A dire lack of global virus surveillance doesn't negate the potential of mutation monitoring, argue two researchers behind the mutant flu research.

Bio-IT World | Imaging in drug discovery has been rising to the forefront of conversations more and more recently. Managing editor Allison Proffitt spoke with Ken Kilgore, Director of Immunology Pharmacology at Janssen Research & Development (formerly Centocor Research & Development), a Johnson & Johnson company, about how—and why—imaging’s role is changing in drug discovery.

Dana-Farber Cancer Institute has been awarded a $10 million grant rom the Massachusetts Life Sciences Center to support the expansion of its cancer imaging research program, Mass High Tech reports. Funding for the grant comes from the state’s 10-year, $1 billion Life Sciences Initiative. The money will support the establishment of Dana-Farber's Molecular Cancer Imaging Facility, a $20 million research initiative in South Boston to develop new molecular imaging probes. As MHT reports, the imaging facility will expand several of Dana-Farber’s basic and clinical research enterprisesfocused on developing targeted cancer therapies.

Bio-IT World | The Bush Doctrine: What the industry calls “safety data” covers everything from discovery-oriented in vitro or cell based studies to extensive GLP toxicology study data, voluminous clinical study records, and post-marketing/pharmacovigilance systems. It leads one to wonder: does anyone have informatics systems that allow safety investigators across the pharma enterprise to effectively mine this ocean of information?